

Maurilio Ponzoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2420948/publications.pdf>

Version: 2024-02-01

43
papers

4,124
citations

270111

25
h-index

355658

38
g-index

43
all docs

43
docs citations

43
times ranked

6959
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	3.2	22
2	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	3.3	47
3	Follicular helper T cell signature of replicative exhaustion, apoptosis, and senescence in common variable immunodeficiency. <i>European Journal of Immunology</i> , 2022, 52, 1171-1189.	1.6	9
4	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	1.5	20
5	MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. <i>British Journal of Haematology</i> , 2021, 193, 497-505.	1.2	41
6	Treating life-threatening TAFRO syndrome with interleukin-1 inhibition. <i>European Journal of Internal Medicine</i> , 2021, 87, 121-123.	1.0	3
7	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1928365.	2.1	6
8	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 749-760.	1.5	1
9	B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 968-981.e14.	1.5	85
10	Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches. <i>Pathology</i> , 2020, 52, 15-29.	0.3	33
11	A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. <i>IScience</i> , 2020, 23, 101562.	1.9	27
12	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	2.5	22
13	Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. <i>EBioMedicine</i> , 2020, 61, 103055.	2.7	21
14	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	1.6	106
15	MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA. <i>Retina</i> , 2019, 39, 679-684.	1.0	50
16	Bone marrow endothelial cells sustain a tumor-specific CD8 ⁺ T cell subset with suppressive function in myeloma patients. <i>Oncolmmunology</i> , 2019, 8, e1486949.	2.1	58
17	Clarithromycin as a repurposing drug against MALT lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 913-915.	1.2	23
18	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CART T cells. <i>Nature Medicine</i> , 2018, 24, 739-748.	15.2	947

#	ARTICLE	IF	CITATIONS
19	Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. <i>Blood</i> , 2018, 132, 1561-1567.	0.6	161
20	Myc and the Warburg Effect. <i>Blood</i> , 2018, 132, SCI-12-SCI-12.	0.6	0
21	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	2.2	28
22	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	1.9	39
23	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	2.2	258
24	Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. <i>International Journal of Hematology</i> , 2017, 105, 104-108.	0.7	14
25	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
26	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	2.2	442
27	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016, 14, 1748-1760.	2.9	90
28	Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. <i>Blood</i> , 2015, 126, 1902-1910.	0.6	79
29	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. <i>Blood</i> , 2015, 125, 3580-3587.	0.6	49
30	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. <i>Haematologica</i> , 2015, 100, 1460-1468.	1.7	19
31	Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome. <i>Clinical Cancer Research</i> , 2015, 21, 5164-5172.	3.2	33
32	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	2.9	48
33	Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RAR α and PLZF-RAR α -Driven Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 3685-3694.	3.2	40
34	Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2015, 168, 654-662.	1.2	90
35	A Bitter Effect: Thrombocytopenia Induced by a Quinidine-containing Beverage. <i>American Journal of Medicine</i> , 2014, 127, e1-e2.	0.6	4
36	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	2.9	112

#	ARTICLE	IF	CITATIONS
37	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
38	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 2630-2640.	0.6	46
39	Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells. <i>Blood</i> , 2013, 122, 142-142.	0.6	2
40	Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification. <i>Blood</i> , 2013, 122, 4365-4365.	0.6	0
41	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	0.6	301
42	Modeling the Genotoxicity of Viral Vector Integration in a Tumor Prone Hematopoietic Stem Cell Transplantation Model.. <i>Blood</i> , 2006, 108, 451-451.	0.6	0
43	Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. <i>Oncotarget</i> , 0, 7, 41725-41736.	0.8	9